Compare UCL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | NTRB |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Hong Kong | United States |
| Employees | 429 | 3 |
| Industry | Telecommunications Equipment | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 44.2M |
| IPO Year | 2019 | N/A |
| Metric | UCL | NTRB |
|---|---|---|
| Price | $1.01 | $3.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.4K | 7.5K |
| Earning Date | 05-20-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.42 |
| 52 Week High | $4.19 | $11.68 |
| Indicator | UCL | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 20.42 | 37.29 |
| Support Level | N/A | $3.44 |
| Resistance Level | $1.38 | $4.24 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 5.88 | 3.95 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.